all-P-ambo-3'-deoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2’a?5’)-P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2’a?5’)-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoguanylyl-(2’a?5’)-P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a?5')P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoguanylyl-(2'a?5')-P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2’a?5’)-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2’a?5’)-P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a?5')-P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2’a?5’)-P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a?5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a?5')-P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a?5')-P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a?5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a?5')-P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a?5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoguanylyl-(2'a?5')-P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a?5')-P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a?5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a?5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoguanylyl-(2'a?5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a?5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a?5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a?5')-2',3'-trideoxy-2',3'-imino-2',3'-secocytidine
Duchenne Muscular Dystrophy
NS Pharma, Inc.nucleic_acidPhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
55 Active assets in the Duchenne Muscular Dystrophy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Viltolarsen NS Pharma, Inc. | Phase 4 | BBB |
Aoc 1044 Avidity Biosciences, Inc. | Phase 3 | BB |
Delandistrogene Moxeparvovec Sarepta Therapeutics, Inc. | Phase 3 | BB |
Golodirsen Rare Disease Research, LLC | Phase 4 | BB |
Avi-4658 Sarepta Therapeutics, Inc. | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →